Q3 2025 Conmed Corp Earnings Call Transcript
Key Points
- Conmed Corp (CNMD) reported a 6.7% year-over-year sales growth, with strong performance in general surgery and orthopedics.
- The company achieved a 2.9% increase in adjusted diluted earnings per share compared to the prior year quarter.
- BioBrace and Foot and Ankle platforms are driving growth within the orthopedics portfolio, with BioBrace being used in over 70 distinct procedures.
- The Buffalo Filter and AirSeal platforms in the general surgery portfolio continue to show strong performance and long-term potential.
- Conmed Corp (CNMD) has initiated a $150 million share repurchase program, enhancing financial flexibility and aligning with long-term shareholder value creation.
- The adjusted gross margin for the third quarter was 56.1%, reflecting a 40 basis point decline compared to Q3 of 2024.
- New tariffs contributed to a 20 basis point headwind in gross margin.
- The company suspended its dividend policy to prioritize share repurchases, which may not be favorable to all investors.
- Despite improvements, the supply chain issues in the orthopedics segment are not fully resolved, impacting market share recovery.
- The company faces ongoing challenges with tariffs, which are expected to continue affecting financial performance.
Good day, and thank you for standing by. Welcome to Conmed's third quarter fiscal 2025 earnings conference call. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, Please press star 1-1 again. Please be advised that today's conference is being recorded.
Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, its plans and objectives. These statements represent the forward-looking statements that involve risk and uncertainties, as those terms are defined under the federal securities laws. Investors are cautioned that any such forward-looking statements are not guarantees of future events, performance, or results.
The company's actual results may differ materially from its current expectations. Please refer to the risk
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
